BioVaria initiated the following success stories:
"I was quite impressed by last year's BioVaria which brought me in contact with various new biochemical technologies and - more importantly - with quite a few bio business insiders and leaders. As a consequence by one of those contacts, I have successfully invested in a young promising startup company which seems to develop very well. Be sure that I will register at this year’s BioVaria again. I can’t wait to see what has happened over the last 12 months."
Peter Jochum, Business Angel
"BioVaria’s format offers a unique setting for networking between scientists, investors, entrepreneurs, industry and technology transfer professionals from across Europe. The Speed Dating, in particular, between young entrepreneurs and investors/coaches during the Spin-off Partnering session provides both sides an excellent chance to meet and exchange valuable feedback."
Andreas Huber, Bayern Kapital (Public VC, founded by the federal state of Bavaria)
"BioVaria is an essential event on our conference calendar, both because of its format and attendees. We have attended for the past few years and found it a unique opportunity for networking with academics, technology transfer organisations and industry in Europe and we have formed many valuable business relationships through contacts made at BioVaria."
Meera Swami, Business Development Manager, MRC Technology
"At BioVaria 2014 we had the opportunity to discuss two of our technologies with industry attendees. As a result, two CDAs were signed and we are continuously communicating with all potential partners to determine the best route of commercialization. BioVaria 2015 was again a success for us with CDAs signed covering two additional technologies. The chances to find the right partner for a project are substantially increased by participating in the BioVaria showcase event."
Jaromír Zahradka, IOCB TTO
SuppreMol obtains license for RA antibody from the University Hospital Regensburg
24 July, 2012 – The Bayerische Patentallianz GmbH, the central patent and marketing agency of 28 Bavarian universities and universities of applied sciences, licences an antibody directed against interleukin 3 (IL-3), which has been generated at the University Hospital Regensburg, to SuppreMol GmbH, a privately held biopharmaceutical company developing innovative therapeutics for the treatment of autoimmune diseases. The technology could be a promising novel treatment option for Rheumatoid Arthritis.
New Compound for the Treatment of Pancreatic Cancer
Ascenion Receives Equity in Oncology Start-up MBiotec
20 February, 2009 Munich, Germany – Ascenion GmbH announces today that it is taking an equity position in MBiotec GmbH, a biopharmaceutical company that has recently been founded in order to develop and commercialize the compound MALP-2S for the treatment of cancer. MALP-2 is a lipopeptide originating from mycoplasma that was discovered by Prof. Mühlradt and his team at the Helmholtz Centre for Infection Research (HZI). During 20 years of intensive research, the scientists have characterized the compound in detail, established a process for the production of a synthetic analogue, MALP-2S, and built an extensive set of data demonstrating that MALP-2S can effectively stimulate the human immune system - innate as well as adaptive immunity. Moreover, preclinical studies and a physician sponsored phase I/II trial (1) indicate safety as well as anti-tumour activity of the compound in pancreatic cancer patients. It was during BioVaria 2008, a life-science showcasing event initiated by Ascenion, that these data triggered interest from experienced industry managers.